Disclosed is a monohydrate of an oxodihydropyridine ethyl phenyl pyridine substituted [1,3]oxazinan-2-one compound of formula (Ip1). An example of compounds of formula (Ip1) is (S)-6-(2-hydroxy-2-methylpropyl)-3-((S)-1-(4-(1-(2-hydroxyethyl)-6-oxo-1,6-dihydropyridin-3-yl)phenyl)ethyl)-6-phenyl-1,3-oxazinan-2-one. Also disclosed are pharmaceutical compositions of the compounds and methods for their use in the reduction or control of the production of Cortisol in a cell or the inhibition of the conversion of cortisone to Cortisol in a cell and for the treatment of Type II diabetes mellitus, obesity, glucose intolerance, hyperglycemia, hyperlipidemia, insulin resistance, and dyslipidemia.
